Pfizer Down 77% on Loss of Exubera

Third-quarter earnings take hit on failure of inhaled-insulin drug
By Caroline Miller,  Newser Staff
Posted Oct 18, 2007 7:54 AM CDT
Pfizer Down 77% on Loss of Exubera
Pedestrians walk past Pfizer world headquarters in New York, in this Dec. 4, 2006 file photo. Pfizer Inc., the world's largest drug maker, said Friday, April 20, 2007 its profit fell 18 percent in the first quarter, hurt by one-time charges and disappointing sales of diabetes drug Exubera. Adjusted...   (Associated Press)

The world's largest drug maker took a 77% hit in third-quarter net income after dropping Exubera, its inhaled insulin product. Competition from generic drugs also pulled down sales, Pfizer announced this morning, as the company lowered its 2007 net-income forecast.

In walking away from Exubera, which Pfizer acquired the world-wide rights to last year for $1.4 billion, the company took a $2.8 billion charge. Sales were disappointing—just $4 million for the second quarter of 2007—the company said, as the drug "failed to gain the acceptance of patients and physicians." Sales of Lipitor, Zithromax, Zoloft, and Norvasc all suffered from recent loss of exclusivity. (More Pfizer stories.)

Get the news faster.
Tap to install our app.
X
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.

X